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The diversity and uniqueness of ﬂatworm G protein coupled receptors (GPCRs) provides impetus for
identifying ligands useful as tools for studying ﬂatworm biology, or as therapeutics for treating diseases
caused by parasitic ﬂatworm infections. To catalyse this discovery process, technologies optimized for
mammalian GPCR high throughput screening need be transposed for screening ﬂatworm GPCRs. Here,
we demonstrate the utility of a genetically encoded cAMP biosensor for resolving the properties of an
abundantly expressed planarian serotonergic GPCR (S7.1R). Application of this methodology resolved the
real time kinetics of GPCR modulation by ligands and demonstrated a marked difference in the kinetic
action of antagonists at S7.1R. Notably, bromocriptine caused a protracted inhibition of S7.1R activity
in vitro and a protracted paralysis of planarian movement, replicating the effect of S7.1R in vivo RNAi. The
lengthy inhibition of function caused by bromocriptine at this abundantly expressed GPCR provides a
useful tool to ablate serotonergic signaling in vivo, and is a noteworthy feature for exploitation as an
anthelmintic vulnerability.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Parasitic ﬂatworm infections cause a variety of diseases in
humans and livestock. Schistosomiasis, a diseasewhich infects over
200million people worldwide, is the most crippling parasitic worm
infection in terms of health and economic impact. Chronic schis-
tosome infections damage internal organs with clinical outcomes
spanning gastrointestinal and liver pathologies, genitourinary dis-
ease, anemia, undernutrition, retarded pediatric growth and
development and a heightened risk for comorbidities (Colley et al.,
2014). Cestode infections also present a healthcare concern: a
prime example being Taenia solium infections that progress to
central nervous system involvement and neurocysticercosis, a
leading course of acquired epilepsy in the developing world.
Beyond human disease, parasitic ﬂatworm infections of sheep,
cattle and ﬁsh cause signiﬁcant agricultural impact. Consequently,
it is important that anthelmintic medications continue to be efﬁ-
cacious, and supported by a discovery pipeline harboring novel li-
gands to anticipate the potential emergence of drug resistanceurch St SE, Minneapolis, MN,
t).
Ltd on behalf of Australian Society fassociated with existing treatments.
In this regard, sequencing data has demonstrated the existence
of a broad portfolio of G protein coupled receptors in ﬂatworms
(~500 in Schmidtea mediterranea, ~100 in Schistosoma mansoni,
estimates, ~60 in E. multilocularis (Zamanian et al., 2011; Tsai et al.,
2013; Saberi et al., 2016)), the biology and ligand speciﬁcities of
which are largely unexplored. These GPCRs represent attractive
targets for drug design given the precedence for GPCR modulators
predominating the human disease pharmacopeia, where a major
proportion of marketed drugs are direct ligands, or modulators, of
GPCR evoked signals (Roth and Kroeze, 2015). The structural
divergence of ﬂatwormGPCR sequences, enhanced by the existence
of ﬂatworm-speciﬁc clades, highlights the potential for discovering
novel GPCR ligands that modulate ﬂatworm biology, and poten-
tially act as novel therapeutics that disrupt parasite GPCR signaling.
To accelerate the discovery of ﬂatworm selective GPCR ligands,
it will be necessary to apply high throughput screening (HTS) ap-
proaches against ﬂatworm GPCRs. This will require transposition of
the same high throughput, scalable reporter technologies that have
catalyzed drug development for human GPCRs. Of particular utility
are genetically encoded biosensors of second messenger activity,
designed to resolve GPCR activity in real time within intact cells.
These probes enable resolution of the kinetic modulation of GPCRor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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assay design and throughput relative to ﬁxed endpoint methods in
broken cell preparations (e.g. radioimmunoassays), and possess
sufﬁcient sensitivity to resolve different classes of GPCR ligands.
Such genetically-encoded sensors are available for Ca2þ (Kotlikoff,
2007) and cAMP (Fan et al., 2008; Binkowski et al., 2011b), as
well as a further toolbox of probes for directly monitoring GPCR
function (Clister et al., 2015). However, these approaches have yet
to bewidely adopted to proﬁle ﬂatwormGPCRs (Chan et al., 2016b).
Here we demonstrate the use of a genetically encoded cAMP
biosensor to resolve the properties and ligand binding speciﬁcity of
different ﬂatworm GPCRs. First, we exploit the real time kinetic
resolution of this technology to demonstrate an unusually pro-
tracted inhibition of signaling at an abundant planarian seroto-
nergic GPCR elicited by the ergot alkaloid bromocriptine. This
behavior likely contributes to the protracted paralysis of intact
planarian worms exposed to bromocriptine, and represents an
intriguing and exploitable aspect of receptor phenomenology for
anthelmintic drug design. Second, in the companion paper (Chan
et al., 2016a), we demonstrate the utility of this technology for
characterizing the interaction of a group of structurally related
aporphine ligands with a schistosome serotonergic GPCR
(Sm.5HTRL). Collectively, both studies evidence the capacity to
characterize ﬂatworm GPCR properties with a reporter technology
compatible with HTS campaigns.
2. Materials and methods
2.1. Chemicals
Drugs for GPCR assays and planarianmobility experiments were
obtained from Sigma Aldrich: bromocriptine (B2134), cyprohepta-
dine (C3280000), serotonin (H9523), praziquantel (P4668), mian-
serin (M2525) and 3-Isobutyl-1-methylxanthine (IBMX, I5879).
2.2. Cell culture and cAMP assays
Low passage (~5e25) HEK293 cells (ATCC CRL-1573.3) were
cultured in growth medium (DMEM, 10% heat inactivated fetal
bovine serum, penicillin (100 units/ml), streptomycin (100 mg/ml),
and L-glutamine (290 mg/ml)). For GPCR functional assays, adherent
HEK293 cells cultured in growth medium without penicillin and
streptomycin were transiently transfected (Lipofectamine 2000,
Thermo Fischer) at 80% conﬂuence approximately 16 h after
seeding in T-25 cell-culture ﬂasks. Transfections consisted of a
human codon optimized S7.1R construct (Dugesia japonica S7.1R,
Dj-S7.1R, GenBank accession number AB004540.1) subcloned into
the pCS2() mammalian expression vector and the pGloSensor™-
22F cAMP construct (Promega, Cat. #E2301) delivered at a 1:1 ratio.
One day after transfection, cells were trypsinized and plated in 96
well, solid white plates (Corning, cat # 3917) in DMEM supple-
mented with 1% heat inactivated dialyzed FBS (Gibco). The
following day, media was replaced with 100 mL/well of assay buffer
(HBSS supplemented with 0.1% BSA, 20 mM HEPES (pH 7.4) and
GloSensor™ reagent). Plates were equilibrated at room tempera-
ture for two hours prior to luminescence assays. Luminescence
detection was measured on a GloMax®-Multi Detection System
plate reader (Promega). All assays were performed in the presence
of IBMX (200 mM). Ligands were added at a concentration of 20x
per well (i.e. 5 mL drug stock to 100 mL media/well). Assays for long
lasting effects of antagonists on S7.1R were performed on cellular
suspensions. Transfections were performed as described above,
scaled to 80% conﬂuent T-75 cell culture ﬂasks. The following day,
cells were trypsinized, centrifuged (300 RCF/5 min) and resus-
pended in 10 mL DMEM supplemented with 1% heat inactivateddialyzed FBS. Following treatment with test compounds (1hr), cells
were centrifuged (300 RCF/5 min) and the media was exchanged
for DMEM. Re-suspension and centrifugation were repeated
washing a total of three times. After the last wash, cells were
resuspended in the assay buffer described above and gently rotated
to prevent settling over the course of the equilibration period. Cells
were then plated in 96well, solid white plates (100mL/well) in order
to assay 5-HT responsiveness.
2.3. Planarian mobility assays
A clonal line of Dugesia japonica (GI strain) was used for these
experiments. Planarian husbandry was performed as described
previously (Chan and Marchant, 2011) with worms maintained at
room temperature and fed weekly. For mobility experiments,
worms were transferred to a glass watchglass (50 mm diameter,
Fisher Scientiﬁc) centered over a LED backlit light (Edmund Optics,
#83-873). Behavior was recorded using an immobilized digital
video camera (Canon VIXIA HF R400). For ease of evaluation, ex-
periments are presented as minimal intensity projections to pro-
vide a qualitative visual readout of worm motion over the
timecourse of the entire experiment. Between recordings, worms
were returned to petri dishes. For experiments examining the onset
of paralysis, ﬁlming started immediately after exposure of worms to
drug-containing solution in the glass watchglass. Movement videos
were processed using custom written algorithms in Ctrax to track
the motility of individual worms (Branson et al., 2009). Motionwas
scored by quantifying total distance travelled (mm) over the ﬁxed
recording interval and averaged for the 10 worms in each assay.
Errors in tracking were corrected using the Fix Errors MATLAB
Toolbox and descriptive statistics were computed using scripts in
the Behavioral Microarray MATLAB Toolbox and custom written
algorithms in MATLAB.
2.4. Planarian RNAi
Knockdown of Dugesia japonica S7.1R was performed by a
feeding protocol described previously (Chan and Marchant, 2011;
Chan et al., 2015). Brieﬂy, a region corresponding to 46-1353bp of
the S7.1R coding sequence was subcloned into the pDONR RNAi
vector and transformed into HT115(DE3) RNase deﬁcient bacteria,
permitting IPTG induced expression of dsRNA against the target
gene product. Bacterial pellets mixed in a slurry of chicken liver
homogenatewere fed to cohorts of approximately 100worms three
times over the course of one week, followed by a cycle of enforced
regeneration (amputation of head and tail fragments). This feeding
and regeneration protocol was repeated, and one week after
amputation regenerated animals were assayed for movement
phenotypes.
3. Results
3.1. Functionality of a heterologous expressed planarian 5-HT GPCR
resolved using a cAMP biosensor
Free living planarian ﬂatworms can be a tractable model for
predicting drug efﬁcacies and identifying novel druggable targets
in parasitic helminths (Chan et al., 2014). For example, the ability to
combine genetic (in vivo RNAi) and pharmacological manipulations
in this system has provided insight into the pathways engaged by
the anthelmintic praziquantel (PZQ) in this model (Nogi et al.,
2009; Zhang et al., 2011; Chan et al., 2014), as well as the identiﬁ-
cation of ligands that phenocopy PZQ action which may augur
anthelmintic efﬁcacy (Chan et al., 2014, 2015). Serotonergic G
protein coupled receptors (GPCRs) are one such class of targets,
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signatures and roles in ﬂatworm biology.
Transcriptomic proﬁling of the planarian Dugesia japonica has
revealed as many as 17 predicted serotonergic GPCRs distributed
within three groupings (S1, S4 and S7; (Chan et al., 2015)) deﬁned
through homology with Caenorhabditis elegans serotonin receptors
(SER1, SER4 & SER7; (Komuniecki et al., 2004; Zamanian et al.,
2011)). The most abundantly expressed 5-HT receptor (by FPKM
values) was named S7.1R (equivalent to 5HTLpla4 (Saitoh et al.,
1997)) and shown to be neuronally expressed (Fraguas et al.,
2012). In vivo RNAi experiments revealed S7.1R to regulate
planarian mobility and regenerative polarity (Chan et al., 2015). For
example, knockdown of S7.1R resulted in a >80% decrease in the
distance travelled by individual worms over a 2 min recording
period (Fig. 1A). Pharmacological characterization of this receptor
and resolution of the effects of S7.1R ligands on neuromuscular
function and planarian regeneration is therefore of interest.
To enable such analyses, we heterologously expressed a codon-
optimized version of S7.1R in HEK293 cells, together with a
genetically encoded biosensor for cAMP. The cAMP biosensor used
functions as a luminescence reporter. The probe reports changes in
intracellular cAMP through changes in luminescence emission
consequent to binding of cAMP to a cAMP-binding domain inserted
within the recombinant ﬁreﬂy luciferase (Binkowski et al., 2011a,
2011b). Luminescence can therefore be resolved over time in
intact cells, enabling kinetic proﬁling of responses to ligands, anFig. 1. Heterologous expression of a planarian 5-HT receptor. (A) Comparison of mobility o
RNAi. Left eminimal intensity overlay of images from a 2 min recording of respective RNAi co
of 10 worms for each RNAi condition. Data analysed from (Chan et al., 2015). P value, ** ¼ p <
with S7.1R and a cAMP dependent luciferase (black circles) or a cAMP-dependent luciferase
peak luminescence amplitude in cells transfected with S7.1R and a cAMP dependent luci
responsiveness (1 mM) of 7.1R expressing cells co-treated with bromocriptine (BRM, white
says, and represent mean ± s.d (B,C,D),or mean ± s.e.m. (A).improvement over single (‘endpoint’) measurements from broken
cells. The rationale for this approach was based upon the prior
demonstration of coupling of the Dugesia tigrina S7.1R homologue
(Dt.Ser1, (Zamanian et al., 2012)) and the schistosome S7.1R ho-
mologue (Sm.5HTR) to the cAMP signaling pathway (Patocka et al.,
2014; Chan et al., 2016b).
Addition of 5-HT to HEK293 cells expressing the biosensor
construct failed to change luminescence levels, while addition of 5-
HT to HEK293 cells co-expressing S7.1R evoked a robust increase in
luminescence (Fig. 1B). Quantiﬁcation of the amplitude of the 5-HT
evoked signal over a range of 5-HT concentrations yielded a dose-
response relationship with an EC50 ¼ 82 ± 5 nM, compared with
a lack of response fromHEK293 cells transfectedwith the biosensor
alone (Fig. 1C). Addition of agonist caused a ~6e10-fold change in
luminescence levels, a smaller range than observed with Sm.5HTR
(Chan et al., 2016b), owing to a higher basal level of activity in cells
expressing S7.1R. This basal activity likely relates to a low level of
constitutive coupling to Gs in cells expressing S7.1R.
The effect of preincubation with serotonergic blockers was then
examined. Preincubationwith bromocriptine, an ergot alkaloid that
inhibits ﬂatwormmovement (Chan et al., 2014, 2015) blocked 5-HT
evoked signals (Fig. 1D). Similarly cyproheptadine, a known
antagonist of 5-HT responses in ﬂatworms (Mellin et al., 1983;
Willcockson and Hillman, 1984; Patocka et al., 2014) also caused a
dose-dependent inhibition of 5-HT evoked cAMP generation. These
experiments demonstrated both these compounds behaved as S7.1f cohorts of D. japonica ﬂatworms with either a control gene or S7.1R targeted by in vivo
horts (10 worms) within a watchglass. Right - Quantiﬁcation of movement for 3 cohorts
0.01. (B) Kinetics of 5-HT (1 mM) evoked cAMP generation in HEK293 cells transfected
alone (white circles). (C) Dose response relationship of effects of 5-HT concentration on
ferase (black circles) or a cAMP-dependent luciferase alone (white circles). (D) 5-HT
circles) or cyproheptadine (CYPH, grey circles). Data are representative of n  3 as-
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4.3 ± 0.6 mM for cyproheptadine).
3.2. Comparison of the effects of bromocriptine and cyproheptadine
on intact worms
The effects of both S7.1R antagonists were then studied against
intact planarians. Exposure of worms to either bromocriptine or
cyproheptadine resulted in a dose-dependent inhibition of
planarian motility (Fig. 2A). To compare the inhibitory proﬁle of
these drugs, movement of individual worms was tracked at various
doses of either antagonist. Following image processing, doses were
selected at equivalent points on the dose-inhibition curve corre-
sponding to a concentration that caused 75% inhibition of worm
movement (Fig. 2B&C). This level of inhibition was selected as a
dose which caused individual worms to remain localized in the
watchglass, such that worm trajectories rarely intersected (aster-
isks, Fig. 2A). For bromocriptine the selected dose was 5 mM, and for
cyproheptadine the selected dose was 50 mM, a higher concentra-
tion to effect a similar level of paralysis.
After 20min of exposure to these test doses, the timecourse of
recovery of mobility was then examined following a single media
exchange to drug-free solution. For cyproheptadine, worms
regained normal motility within the course of a few hours (Fig. 3A).
In contrast, the duration of inhibition with bromocriptine was
considerable: worms remained immobilized >24hrs (Fig. 3A).
Quantiﬁcation of these movement videos underscored the differ-
ential kinetics of these drug effects. Whileworms recovered quickly
after cyproheptadine removal (Fig. 3B), worms required several
days to regain normal motility following bromocriptine exposure
(Fig. 3C). This protracted inhibition of mobility was not due to aFig. 2. Bromocriptine and cyproheptadine impair D. japonica movement. (A) Dose depe
doses of bromocriptine (BRM, top), or cyproheptadine (CYPH, bottom). (B&C) Quantiﬁcation
to controls. Data are representative of n  3 assays, and represent mean ± s.e.m.deleterious effect of bromocriptine on the animals, as the inhibition
was fully reversible within a week under these experiment condi-
tions (Fig. 3A&C). Other drugs that inhibited planarian mobility e
mianserin, and the anthelmintic praziquantel e were also exam-
ined, and their effects like cyproheptadine were found to be readily
reversible (Fig. 3D). Mianserin serves as another example of a S7.1R
antagonist, observed to inhibit 5-HT evoked cAMP generation
(Fig. 3D). In contrast, the paralysis caused by PZQ was not attrib-
utable to S7.1R blockade (Fig. 3D).
To examine the possibility that slow exchange of bromocriptine
with worm tissues contributed to the protracted paralysis, the ki-
netics of onset of paralysis was examined. Continual recording of
worm motility after drug exposure conﬁrmed a slower onset of
paralysis for bromocriptine compared with cyproheptadine (Fig. 4).
Reversal of bromocriptine evoked paralysis was also accelerated by
repeated solution exchanges (data not shown), further implicating
a slower equilibration of bromocriptine in the intact organism.
From these experiments, we conclude that the S7.1R antagonists
bromocriptine and cyproheptadine (Fig. 1) both inhibit planarian
mobility (Fig. 2). However the compounds differ in their timecourse
of inhibition of planarian movement (Figs. 3 and 4), with bromo-
criptine causing a potent, protracted inhibition of movement which
reverses slowly in vivo.
3.3. Protracted blockade of S7.1R by bromocriptine in vitro
Is the long lasting action of bromocriptine solely attributable to
differential pharmacokinetics of drug accumulation and efﬂux
in vivo? To address this issue, the inhibitory proﬁle of these two
antagonists were rescreened against the heterologously expressed
S7.1R in vitro. To characterize the kinetics of S7.1R inhibition inndent inhibition of planarian movement following exposure (20min) to the indicated
of worm mobility in (B) bromocriptine or (C) cyproheptadine treated samples relative
Fig. 3. Bromocriptine effects a long lasting impairment of planarian movement. (A) D. japonica mobility before (pre) or at various time periods after a 20 min exposure (post
drug, spanning time ¼ ‘0’ to 1 week) to the S7.1R antagonists bromocriptine (BRM, 5 mM) and cyproheptadine (CYPH, 50 mM). (B&C) Quantiﬁcation of images shown in (A) before
and after drug washout. Each datapoint represents the mobility of a single worm (3 petri dishes, 10 worms in each dish). Plotted line connects the population mean for each
condition. (D) Minimum intensity projections show movement proﬁles for worms treated with no drug (top), mianserin (middle; 10 mM, 20 min) and PZQ (bottom; 75 mM, 15 min),
before drug exposure (left), during drug exposure (middle) and 2hrs after drug removal (right). (E) Effects of mianserin (10 mM) and praziquantel (100 mM) on 5-HT (1 mM) evoked
cAMP signaling through the S7.1R. PZQ, unlike mianserin, did not block 5-HT action at the planarian S7.1R. Data are representative of n  3 assays, and represent mean ± s.e.m. P
value, * ¼ p < 0.05.
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incubatedwith experimental samples (60mins) then removed from
cells followed by a drug-free incubation period (90mins), prior to
reassessment of 5-HT responsiveness (Fig. 5A). For cyproheptadine,
5-HT responsiveness was fully regained following removal of
cyproheptadine, with the kinetics of 5-HT evoked cAMP elevationresembling control cells (Fig. 5B). In contrast, 5-HT signaling
remained depressed in cells previously exposed to bromocriptine
(Fig. 5B), despite drug removal. These data indicate a transient
exposure to bromocriptine caused a prolonged inhibition of S7.1R
signaling activity when the receptor was heterologously expressed
inmammalian cells. This effect was not associatedwith a prolonged
Fig. 4. Kinetics of movement inhibition evoked by S7.1R blockers. (A) Minimum intensity projections showing worm tracks prior to bromocriptine (5 mM, top) or cyproheptadine
(50 mM, bottom) exposure (‘pre’), immediately after drug addition (‘0’) and at 5 min intervals thereafter. (B) Mean worm motility (3 petri dishes, 10 worms in each dish) from
experiments as shown in (A) prior to, and after exposure to indicated drugs. Data are representative of n  3 assays, and represent mean ± s.e.m.
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tion remained robust after incubation with either antagonist
(Fig. 5C). Therefore, the kinetics of S7.1R blockade by bromocriptine
and cyproheptadine were also distinct ex vivo.4. Discussion
Here, we have demonstrated the application of a genetically
encoded cAMP biosensor to proﬁle the properties of a planarian
serotonin receptor (S7.1R). The S7.1 receptor is of interest as it is the
most abundant planarian 5-HT receptor and has a demonstrated
role in regulating planarian neuromuscular biology (Fig. 1A) and
regenerative polarity (Chan et al., 2015). The application of this
methodology is important, as it will be enabling for efforts to
characterize the behavior and pharmacological properties of ﬂat-
worm GPCRs. The technique is sensitive, compatible with real timemeasurements in live cells (Fig. 1) and is amenable to miniaturi-
zation to facilitate higher throughput drug screening campaigns
against ﬂatworm GPCRs (Chan et al., 2016b). Obviously, this
approach method is useful only for GPCRs that modulate cellular
cAMP levels (Gs, Gi), but this reﬂects a coupling speciﬁcity of the
majority of ﬂatworm GPCRs examined in heterologous systems to
date (Omar et al., 2007; Taman and Ribeiro, 2009; Zamanian et al.,
2012; Patocka et al., 2014; MacDonald et al., 2015). Probes for other
secondmessenger pathways (for example genetically encoded Ca2þ
indicators) are available and have also been shown to be useful for
deorphanizing lophotrochozoan GPCR activity (Bauknecht and
Jekely, 2015).
Here, we demonstrate the utility of this cAMP biosensor for
resolving aspects of planarian GPCR function. These experiments
yielded the interesting observation that the kinetics of S7.1 receptor
inhibition varied considerably with different S7.1R ligands. While
Fig. 5. Bromocriptine results in a long lasting impairment of S7.1R activity. (A) Outline of experimental workﬂow. HEK293 cells were co-transfected with S7.1R and a cAMP
reporter and pre-incubated (60 min) with vehicle (DMSO), or S7.1R antagonist (bromocriptine, cyproheptadine; 10 mM), which was washed out prior to assaying for 5-HT
responsiveness (90 min later). (B) Kinetics of 5-HT (1 mM) evoked cAMP generation in cells pre-treated with either vehicle control (DMSO, black circles), bromocriptine (10 mM,
white circles) or cyproheptadine (10 mM, grey circles). (C) Quantiﬁcation of 5-HT (1 mM) response (left) and forskolin (20 mM) response (right) for individual drug treatments. Data
are representative of n  3 assays, and represent mean ± s.d (B) or mean ± s.e.m (C). P value, ** ¼ p < 0.01.
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generation in a heterologous expression assay (Fig. 1), the duration
of receptor inhibition persisted considerably longer for bromo-
criptine (Fig. 5). Cyproheptadine (and mianserin) inhibition
reversed more rapidly, consistent with these drugs behaving as
competitive, reversible S7.1R antagonists. A similar kinetic diver-
gence was also observed for these two drugs at the schistosome
Sm.5HTR receptor (Chan et al., 2016b). In intact planarians, diver-
gent kinetic proﬁles were also resolved, with bromocriptine-
evoked inhibition of worm motility persisting for days, whereas
normal motility was regained within 2 h after removal of an
equivalent dose of cyproheptadine (Fig. 3). Transient exposure to
bromocriptine also caused a long lasting inhibition of adult schis-
tosome movement (Chan et al., 2016b). This observation that
bromocriptine has temporally penetrant effects beyond the period
of exposure to a bolus dosage has potential signiﬁcance for treating
parasitic ﬂatworm infections, if a single dose regimen in the ﬁeld
effects a persistent paralysis of the parasite. For praziquantel, the
standard anthelmintic therapy, the duration for which plasma PZQ
concentrations exceed the minimal effective concentration is brief,
necessitating multiple dosing on a single day, ideally reinforced by
subsequent treatments, for maximal clinical efﬁcacy (King et al.,
2011; Olliaro et al., 2014). Such a multiple dosing regimen can
rarely be executed in disadvantaged health care environments for
practical reasons. Therefore, the observed kinetics properties of
bromocriptine interaction with ﬂatworm serotonin receptors could
represent a highly attractive piece of ligand-receptor phenome-
nology to exploit for treating parasitic disease.
What is the mechanism underpinning this behavior? The short
answer is that we do not currently know, but several options merit
discussion. A ﬁrst consideration would be whether bromocriptine
causes a protracted inhibition because the drug exhibits a lengthy
elimination timecourse in vivo. This could occur if the drug was
converted into an active metabolite, or the physiochemical prop-
erties cause the drug to be sequestered within ﬂatworm tissues.
Further experiments would be needed to investigate these possi-
bilities, but our observations that this behavior is manifest in vitro
on the S7.1 receptor heterologously expressed in mammalian cells
lessens the likelihood that whole organism pharmacokinetics
provide the complete explanation.
Second, do the properties of the S7.1 receptor provide any
insight into this phenomenon? The S7.1 receptor is the most pre-
dominantly expressed serotonin receptor in Dugesia japonica
(FPKM values, (Chan et al., 2015)). The S7 clade, named on account
of homology to the C. elegans SER7 receptor, most closely resemblesthe human 5-HT7 receptor (Hs.5HTR7). Intriguingly, Hs.5HTR7
displays an unusual phenomenon of persistent inactivation caused
by a subset of ligands (Smith et al., 2006). Bromocriptine has been
identiﬁed as one such ‘inactivating antagonist’ (Knight et al., 2009).
Other ‘inactivating antagonists’ derive from diverse chemical clas-
ses, and include risperidone, 9-OH risperidone (a metabolite, see
above), methiothepin and several ergot alkaloids (lisuride, meter-
goline and bromocriptine). The persistent inactivation of receptor
signaling has been ascribed to a pseudo-irreversible binding of
these ‘inactivator’-like compounds to Hs.5HTR7, and potentially
other GPCRs (Teitler and Klein, 2012), stabilizing a receptor
conformation that inactivates associated G proteins and effectors
(Toohey et al., 2009). The same class of compounds identiﬁed as
inactivating antagonists at Hs.5HTR7 cause a protracted inactiva-
tion at the predominant schistosome 5.HTR (Sm.5HTR, (Chan et al.,
2016b)) and on the basis of the data reported here (Fig. 4), this
property appears conserved at a free living ﬂatworm serotonergic
GPCR.
Third, does the compound class provide any insight? Bromo-
criptine is a synthetic brominated ergopeptide, belonging to the
ergot alkaloid class of compounds which we have recently shown
are potent regulators of planarian neuromuscular function (Chan
et al., 2015). The action of ergot alkaloids against smooth muscle
has long been appreciated, as has the efﬁcacy of ergot alkaloids
against ﬂatworms (Hillman et al., 1974; Tomosky et al., 1974).
Despite the historical importance of this compound grouping,
much remains to be resolved about the interaction of ergots with
bioaminergic GPCRs and their ability to bias signaling outcomes
(Wacker et al., 2013;Wang et al., 2013), their action in vivo (Carhart-
Harris et al., 2016), and the therapeutic malleability that derives
from their notorious polypharmacology (Besnard et al., 2012). Of
particular interest to our observations is the observation that ergot
alkaloids display slow receptor association and dissociation kinetics
at a heterologously expressed human 5-HT2B GPCR (Unett et al.,
2013). For example, the half time for dissociation of cabergoline
was ~17-fold longer than for 5-HT (100mins versus 6mins). These
data evidencing slow on and off rates of ergot alkaloids at the re-
ceptor level provides another explanation for the lengthy duration
of the bromocriptine-evoked paralysis.
In conclusion, use of a real-time cAMP biosensor to study the
properties of an abundant planarian 5-HT receptor has revealed a
protracted inhibition of receptor signaling caused by bromocrip-
tine. These data advance bromocriptine as a pharmacological tool
for effecting protracted inhibition of 5-HT signaling in platyhel-
minths (akin to a pharmacological ‘knockout’). Whatever the
J.D. Chan et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 356e363 363mechanistic explanation for this effect, the key point is that this
receptor phenomenology occurs at a prevalent and widely
conserved 5-HT GPCR in ﬂatworms and affords an encouraging
vulnerability for directed drug design. Application of this screening
method to other GPCRs should aid discovery of new ligands to help
dissect the basic biology of GPCR signaling in ﬂatworms.
Acknowledgements
This work was supported by the National Science Foundation
(MCB1615538).
References
Bauknecht, P., Jekely, G., 2015. Large-scale combinatorial deorphanization of pla-
tynereis neuropeptide GPCRs. Cell Rep. 12, 684e693.
Besnard, J., Ruda, G.F., Setola, V., Abecassis, K., Rodriguiz, R.M., Huang, X.P.,
Norval, S., Sassano, M.F., Shin, A.I., Webster, L.A., Simeons, F.R., Stojanovski, L.,
Prat, A., Seidah, N.G., Constam, D.B., Bickerton, G.R., Read, K.D., Wetsel, W.C.,
Gilbert, I.H., Roth, B.L., Hopkins, A.L., 2012. Automated design of ligands to
polypharmacological proﬁles. Nature 492, 215e220.
Binkowski, B.F., Butler, B.L., Stecha, P.F., Eggers, C.T., Otto, P., Zimmerman, K.,
Vidugiris, G., Wood, M.G., Encell, L.P., Fan, F., Wood, K.V., 2011a. A luminescent
biosensor with increased dynamic range for intracellular cAMP. ACS Chem. Biol.
6, 1193e1197.
Binkowski, B.F., Fan, F., Wood, K.V., 2011b. Luminescent biosensors for real-time
monitoring of intracellular cAMP. Methods Mol. Biol. 756, 263e271.
Branson, K., Robie, A.A., Bender, J., Perona, P., Dickinson, M.H., 2009. High-
throughput ethomics in large groups of Drosophila. Nat. Methods 6, 451e457.
Carhart-Harris, R.L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W.,
Murphy, K., Tagliazucchi, E., Schenberg, E.E., Nest, T., Orban, C., Leech, R.,
Williams, L.T., Williams, T.M., Bolstridge, M., Sessa, B., McGonigle, J., Sereno, M.I.,
Nichols, D., Hellyer, P.J., Hobden, P., Evans, J., Singh, K.D., Wise, R.G., Curran, H.V.,
Feilding, A., Nutt, D.J., 2016. Neural correlates of the LSD experience revealed by
multimodal neuroimaging. Proc. Natl. Acad. Sci. U. S. A. 113, 4853e4858.
Chan, J.D., Marchant, J.S., 2011. Pharmacological and functional genetic assays to
manipulate regeneration of the planarian Dugesia japonica. J. Vis. Exp. 54
http://dx.doi.org/10.3791/3058 pii: 3058.
Chan, J.D., Agbedanu, P.N., Zamanian, M., Gruba, S.M., Haynes, C.L., Day, T.A.,
Marchant, J.S., 2014. ’Death and axes’; unexpected Ca2þ entry phenologs predict
new anti-schistosomal agents. PLoS Pathog. 10, e1003942.
Chan, J.D., Agbedanu, P.N., Grab, T., Zamanian, M., Dosa, P.I., Day, T.A., Marchant, J.S.,
2015. Ergot alkaloids (Re)generate new leads as antiparasitics. PLoS Negl. Trop.
Dis. 9, e0004063.
Chan, J.D., Acharya, S., Day, T.A., Marchant, J.S., 2016a. Pharmacological proﬁling an
abundantly expressed schistosome serotonergic GPCR identiﬁes nuciferine as a
potent antagonist. Int. J. Parasitol. Drugs Drug Resist. 6, 364e370.
Chan, J.D., McCorvy, J.D., Acharya, S., Johns, M.E., Day, T.A., Roth, B.L., Marchant, J.S.,
2016b. A miniaturized screen of a schistosoma mansoni serotonergic G protein-
coupled receptor identiﬁes novel classes of parasite-selective inhibitors. PLoS
Pathog. 12, e1005651.
Clister, T., Mehta, S., Zhang, J., 2015. Single-cell analysis of G-protein signal trans-
duction. J. Biol. Chem. 290, 6681e6688.
Colley, D.G., Bustinduy, A.L., Secor, W.E., King, C.H., 2014. Human schistosomiasis.
Lancet 383, 2253e2264.
Fan, F., Binkowski, B.F., Butler, B.L., Stecha, P.F., Lewis, M.K., Wood, K.V., 2008. Novel
genetically encoded biosensors using ﬁreﬂy luciferase. ACS Chem. Biol. 3,
346e351.
Fraguas, S., Barberan, S., Ibarra, B., Stoger, L., Cebria, F., 2012. Regeneration of
neuronal cell types in Schmidtea mediterranea: an immunohistochemical and
expression study. Int. J. Dev. Biol. 56, 143e153.
Hillman, G.R., Olsen, N.J., Senft, A.W., 1974. Effect of methysergide and dihydroer-
gotamine on Schistosoma mansoni. J. Pharmacol. Exp. Ther. 188, 529e535.
King, C.H., Olbrych, S.K., Soon, M., Singer, M.E., Carter, J., Colley, D.G., 2011. Utility of
repeated praziquantel dosing in the treatment of schistosomiasis in high-risk
communities in Africa: a systematic review. PLoS Negl. Trop. Dis. 5, e1321.
Knight, J.A., Smith, C., Toohey, N., Klein, M.T., Teitler, M., 2009. Pharmacological
analysis of the novel, rapid, and potent inactivation of the human 5-
Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other
inactivating antagonists. Mol. Pharmacol. 75, 374e380.
Komuniecki, R.W., Hobson, R.J., Rex, E.B., Hapiak, V.M., Komuniecki, P.R., 2004.
Biogenic amine receptors in parasitic nematodes: what can be learned from
Caenorhabditis elegans? Mol. Biochem. Parasitol. 137, 1e11.
Kotlikoff, M.I., 2007. Genetically encoded Ca2þ indicators: using genetics andmolecular design to understand complex physiology. J. Physiol. 578, 55e67.
MacDonald, K., Kimber, M.J., Day, T.A., Ribeiro, P., 2015. A constitutively active G
protein-coupled acetylcholine receptor regulates motility of larval Schistosoma
mansoni. Mol. Biochem. Parasitol. 202, 29e37.
Mellin, T.N., Busch, R.D., Wang, C.C., Kath, G., 1983. Neuropharmacology of the
parasitic trematode, Schistosoma mansoni. Am. J. Trop. Med. Hyg. 32, 83e93.
Nogi, T., Zhang, D., Chan, J.D., Marchant, J.S., 2009. A novel biological activity of
praziquantel requiring voltage-operated Ca2þ channel b subunits: subversion of
ﬂatworm regenerative polarity. PLoS Negl. Trop. Dis. 3, e464.
Olliaro, P., Delgado-Romero, P., Keiser, J., 2014. The little we know about the phar-
macokinetics and pharmacodynamics of praziquantel (racemate and R-enan-
tiomer). J. Antimicrob. Chemother. 69, 863e870.
Omar, H.H., Humphries, J.E., Larsen, M.J., Kubiak, T.M., Geary, T.G., Maule, A.G.,
Kimber, M.J., Day, T.A., 2007. Identiﬁcation of a platyhelminth neuropeptide
receptor. Int. J. Parasitol. 37, 725e733.
Patocka, N., Sharma, N., Rashid, M., Ribeiro, P., 2014. Serotonin signaling in Schis-
tosoma mansoni: a serotonin-activated G protein-coupled receptor controls
parasite movement. PLoS Pathog. 10, e1003878.
Roth, B.L., Kroeze, W.K., 2015. Integrated approaches for genome-wide interrogation
of the druggable non-olfactory G protein-coupled receptor superfamily. J. Biol.
Chem. 290, 19471e19477.
Saberi, A., Jamal, A., Beets, I., Schoofs, L., Newmark, P.A., 2016. GPCRs direct germline
development and somatic gonad function in planarians. PLoS Biol. 14, e1002457.
Saitoh, O., Yuruzume, E., Watanabe, K., Nakata, H., 1997. Molecular identiﬁcation of a
G protein-coupled receptor family which is expressed in planarians. Gene 195,
55e61.
Smith, C., Rahman, T., Toohey, N., Mazurkiewicz, J., Herrick-Davis, K., Teitler, M.,
2006. Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin
receptor. Mol. Pharmacol. 70, 1264e1270.
Taman, A., Ribeiro, P., 2009. Investigation of a dopamine receptor in Schistosoma
mansoni: functional studies and immunolocalization. Mol. Biochem. Parasitol.
168, 24e33.
Teitler, M., Klein, M.T., 2012. A new approach for studying GPCR dimers: drug-
induced inactivation and reactivation to reveal GPCR dimer function in vitro,
in primary culture, and in vivo. Pharmacol. Ther. 133, 205e217.
Tomosky, T.K., Bennett, J.L., Bueding, E., 1974. Tryptaminergic and dopaminergic
responses of Schistosoma mansoni. J. Pharmacol. Exp. Ther. 190, 260e271.
Toohey, N., Klein, M.T., Knight, J., Smith, C., Teitler, M., 2009. Human 5-HT7 receptor-
induced inactivation of forskolin-stimulated adenylate cyclase by risperidone,
9-OH-risperidone and other “inactivating antagonists”. Mol. Pharmacol. 76,
552e559.
Tsai, I.J., Zarowiecki, M., Holroyd, N., Garciarrubio, A., Sanchez-Flores, A.,
Brooks, K.L., Tracey, A., Bobes, R.J., Fragoso, G., Sciutto, E., Aslett, M., Beasley, H.,
Bennett, H.M., Cai, J., Camicia, F., Clark, R., Cucher, M., De Silva, N., Day, T.A.,
Deplazes, P., Estrada, K., Fernandez, C., Holland, P.W., Hou, J., Hu, S., Huckvale, T.,
Hung, S.S., Kamenetzky, L., Keane, J.A., Kiss, F., Koziol, U., Lambert, O., Liu, K.,
Luo, X., Luo, Y., Macchiaroli, N., Nichol, S., Paps, J., Parkinson, J., Pouchkina-
Stantcheva, N., Riddiford, N., Rosenzvit, M., Salinas, G., Wasmuth, J.D.,
Zamanian, M., Zheng, Y., Taenia solium Genome, C., Cai, X., Soberon, X.,
Olson, P.D., Laclette, J.P., Brehm, K., Berriman, M., 2013. The genomes of four
tapeworm species reveal adaptations to parasitism. Nature 496, 57e63.
Unett, D.J., Gatlin, J., Anthony, T.L., Buzard, D.J., Chang, S., Chen, C., Chen, X.,
Dang, H.T., Frazer, J., Le, M.K., Sadeque, A.J., Xing, C., Gaidarov, I., 2013. Kinetics
of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling
onset and duration. J. Pharmacol. Exp. Ther. 347, 645e659.
Wacker, D., Wang, C., Katritch, V., Han, G.W., Huang, X.P., Vardy, E., McCorvy, J.D.,
Jiang, Y., Chu, M., Siu, F.Y., Liu, W., Xu, H.E., Cherezov, V., Roth, B.L., Stevens, R.C.,
2013. Structural features for functional selectivity at serotonin receptors. Sci-
ence 340, 615e619.
Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G.W., Liu, W.,
Huang, X.P., Vardy, E., McCorvy, J.D., Gao, X., Zhou, X.E., Melcher, K., Zhang, C.,
Bai, F., Yang, H., Yang, L., Jiang, H., Roth, B.L., Cherezov, V., Stevens, R.C., Xu, H.E.,
2013. Structural basis for molecular recognition at serotonin receptors. Science
340, 610e614.
Willcockson, W.S., Hillman, G.R., 1984. Drug effects on the 5-HT response of
Schistosoma mansoni. Comp. Biochem. Physiol. C 77, 199e203.
Zamanian, M., Kimber, M.J., McVeigh, P., Carlson, S.A., Maule, A.G., Day, T.A., 2011.
The repertoire of G protein-coupled receptors in the human parasite Schisto-
soma mansoni and the model organism Schmidtea mediterranea. BMC Genomics
12, 596.
Zamanian, M., Agbedanu, P.N., Wheeler, N.J., McVeigh, P., Kimber, M.J., Day, T.A.,
2012. Novel RNAi-mediated approach to G protein-coupled receptor deorpha-
nization: proof of principle and characterization of a planarian 5-HT receptor.
PLoS ONE 7, e40787.
Zhang, D., Chan, J.D., Nogi, T., Marchant, J.S., 2011. Opposing roles of voltage-gated
Ca2þ channels in neuronal control of stem cell differentiation in vivo.
J. Neurosci. 31, 15983e15995.
